PPARD and type 2 diabetes mellitus: In obese patients with type 2 diabetes, rosiglitazone increased insulin sensitization through upregulation of mRNA levels of PPARδ and PGC-1α, as well as stimulation of SDH activity in skeletal muscles [49].